Activity in this selectionApr 30, 2026 · Apr 1, 2026
- Rounds participated in
- 1
- Confirmed lead rounds
- —
1 roles undisclosed- New companies
- 1
First participation on record · 0 follow-on- Funding in participating rounds
- $75M
1 disclosed · full round size, not this investor’s share
Rounds
1 in this selectionAdcendoDevelops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment
Role not disclosed